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Abstract
Background: Written participant information materials are important for ensuring that potential trial participants
receive necessary information so that they can provide informed consent. However, such materials are frequently
long and complex, which may negatively impact patient understanding and willingness to participate. Improving
readability, ease of comprehension and presentation may assist with improved participant recruitment. The Systematic
Techniques for Assisting Recruitment to Trials (MRC START) study aimed to develop and evaluate interventions to
improve trial recruitment. This study aimed to assess the effectiveness of an optimised participant information brochure
and cover letter developed by MRC START regarding response and participant recruitment rates.
Methods: We conducted a study within a trial (SWAT) embedded in the EarlyCDT Lung Cancer Scotland (ECLS) trial that
aimed to assess the effectiveness of a new test in reducing the incidence of patients with late-stage lung cancer at
diagnosis compared with standard care. Potential participants approached for ECLS were randomised to receive the
original participant information brochure and accompanying letter (control group) or optimised versions of these
materials which had undergone user testing and a process of re-writing, re-organisation and professional graphic design
(intervention group). The primary outcome was the number of patients recruited to ECLS. The secondary outcome was
the proportion of patients expressing an interest in participating in ECLS.
Results: In total, 2262 patients were randomised, 1136 of whom were sent the intervention materials and
1126 of whom were sent the control materials. The proportion of patients enrolled and randomised into ECLS
was 180 of 1136 (15.8%) in the intervention group and 176 of 1126 (15.6%) in the control group (OR = 1.016,
95% CI, 0.660 to 1.564). The proportion of patients who positively responded to the invitation was 224 of
1136 (19.7%) in the intervention group and 205 of 1126 (18.2%) in the control group (OR = 1.103, 95% CI, 0.
778 to 1.565).
Conclusions: Optimised patient information materials made little difference to the proportion of patients positively
responding to a trial invitation or to the proportion subsequently randomised to the host trial.
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Background
Whilst randomised controlled trials are the gold standard
for evaluating the effect of treatments, participant recruit-
ment continues to be the biggest obstacle to their success-
ful delivery [1–3]. In the United Kingdom, increasing
numbers of people are approached to participate in trials
[4]. Despite this, the proportion of people who actually
enrol is small, and recruitment remains a challenge, with
between 50% and 80% of all trials not meeting recruitment
targets [2, 5, 6]. Poor recruitment into a trial reduces the
total sample size (limiting internal validity) and the pro-
portion of eligible participants who are recruited (limiting
external validity). Recruitment and retention are now the
highest priority for methodological research in academic
trials units in the United Kingdom [7], and systematic re-
views have highlighted a clear need for recruitment inter-
ventions, especially those evaluated in ongoing trials
where patients make real (rather than hypothetical) deci-
sions about participation [8–10].
Although proper understanding of the trial is funda-
mental to valid participant consent, research suggests
that trial participants can have insufficient understand-
ing of some aspects, including the burdens and rewards
associated with participation as well as their rights to re-
voke consent once enrolled [11, 12]. Furthermore, at the
end of a trial participants may not know the name of the
medicine being evaluated [13]. Usually this information
is provided in the form of a participant information
sheet (PIS); however, PISs are often long and complex,
in part to meet the stipulations of research ethics com-
mittees. They may also lack visual appeal [14, 15] with
suboptimal formatting and writing of the information.
These features can adversely affect prospective partici-
pants’ willingness to engage with the leaflet and so may
go unread. When such leaflets are read, they may affect
potential participants’ understanding of a trial, which in
turn can negatively impact recruitment (and potentially
retention). One way of improving the quality of the PIS
is performance-based user testing. This is an iterative
process that involves obtaining feedback from the target
population for the PIS, expertise in writing for patients
and graphic design, and revising the material, which to-
gether are aimed at producing an optimised version of
participant information materials.
The Systematic Techniques for Assisting Recruitment
into Trials (START) study is a research programme,
funded by the UK Medical Research Council (MRC)
[16], which aimed to increase the evidence base for trial
recruitment by developing a platform to advance the
rapid and robust evaluation of recruitment interventions.
Within START we have developed the methodological
and reporting frameworks for embedding recruitment
studies within a trial (SWAT) [16, 17], and additionally
developed two recruitment interventions (an improved
PIS and a multimedia decision aid), which are being
evaluated in a series of SWATs in multiple host trials to
determine their impact on participant recruitment
within individual trials and across different trial contexts
[18, 19]. Full details of the MRC START study are pro-
vided elsewhere [16].
This article reports the fourth MRC START SWAT
developing and evaluating optimised patient information
materials (with improved readability and ease of com-
prehension) in a host trial evaluating a new test for
screening lung cancer: the EarlyCDT Lung Cancer
Scotland (ECLS) study.
Objectives
We aimed to evaluate the effectiveness of optimised pa-
tient information materials on the numbers of partici-
pants responding to the initial invitation to participate
and the numbers ultimately enrolled in the ECLS trial.
Methods
We report the development of the evaluation of the recruit-
ment intervention in line with the guidelines for reporting
embedded recruitment SWATs, which adapt Consolidated
Standards of Reporting Trials (CONSORT) for recruitment
SWATs [17]. The checklist of items for reporting recruit-
ment SWATs is included as Additional file 1.
Trial design: the ECLS host trial
Lung cancer is the world’s leading cause of
cancer-related mortality and a major source of morbidity
[20]. ECLS aimed to assess the effectiveness of a new
test (EarlyCDT-Lung test) in reducing the incidence of
late-stage lung cancer at diagnosis compared with stand-
ard clinical practice [21]. Half of those enrolling were
randomised to be offered the EarlyCDT-Lung test, a
simple blood test to detect seven autoantibodies to aid
in the risk assessment and early detection of lung cancer.
The other half also had their blood taken, but this was
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not tested as part of the trial. Intervention participants
who had a positive test were followed with an x-ray and
serial computed tomographic imaging 6-monthly for
24 months. Control participants received standard care.
ECLS aimed to recruit 10,000 participants from Glasgow
and surrounding areas in Scotland at the time of the
present study. Recruitment into ECLS occurred between
August 2013 and August 2016.
In ECLS potentially eligible individuals were identi-
fied from general practice (GP) medical records
through an electronic medical record search under-
taken by the Scottish Primary Care Research Network
(SPCRN), which was established in 2002 as a frame-
work to co-ordinate national research activity in pri-
mary care. The SPCRN was also responsible for
accessing patient details, determining eligibility and
mailing trial invitations, which consisted of a
GP-signed letter and a participant information book-
let. Those responding positively to the invitation
could opt into the trial using a posted reply slip, SMS
(text) message, email or telephone. Those meeting the
trial eligibility criteria and providing consent were re-
cruited. The eligibility criteria were patients aged
50 years to 75 years, willing and able to give in-
formed consent for participation in the trial, and
current or ex-smokers with at least a 20-pack-year
history (i.e., smoking at least 20 cigarettes per day for
20 years). If patients had less than a 20-pack-year
smoking history, they had to have a first-degree rela-
tive with a history of lung cancer. The ECLS trial
team did not have access to patients’ details until
they independently contacted the trial team.
Participants who did not respond to the initial invita-
tion letter were sent a reminder letter, written and de-
signed by the ECLS study team, to determine whether
they had received the trial invitation and whether they
were interested in taking part. However, this follow-up
process was only introduced 7 months after the start of
recruitment.
Trial design: the embedded recruitment SWAT
Recruitment into the SWAT took place over a
5-month period (February–June 2014) until the target
sample size of the SWAT was reached. The SWAT
adopted a randomised controlled trial design. Patients
identified as potentially eligible for the ECLS trial
(from GP lists) were individually randomised to either
of the following arms:
1. Control participant information brochure (PIB): the
original ECLS PIB and covering invitation letter
(see Additional files 2 and 3)
2. Intervention PIB: the user-tested PIB and invitation
covering letter (see Additional files 4 and 5).
The recruitment trial included all patients identified as
potentially eligible for the ECLS host trial; there were no
additional inclusion or exclusion criteria. The ECLS trial
team led the implementation of the SWAT in their host
trial, with methodological input from the START team.
ST was a co-investigator on both ECLS and MRC
START and proofread the control PIB in his role on
ECLS before START began. ST played no role in the de-
velopment of the START ECLS participant information
leaflet. No other member of the ECLS team was part of
the START team.
Control intervention: PIB
The control PIB was developed by the ECLS host trial
team, based at Tayside Clinical Trials Unit (TCTU). This
was presented as a booklet of 32 pages in length and
approved by The East of Scotland Research Ethics Com-
mittee REC1 on 16th April 2013 (reference 13/ES/0024)
as part of the ethics application for the ECLS study. Un-
like most participant information leaflets in trials, which
tend to be written as plain text documents, the control
PIB was a coloured document formatted by a professional
design company and included photos (Additional file 2).
The accompanying GP letter was on a single A4-sized
sheet with a tear-off reply slip and contact details on the
reverse (Additional file 3).
One of the MRC START investigators (ST) proofread
the content of the control PIB in his former role as the
assistant director of TCTU and a co-investigator on
ECLS. ST’s role in the control PIB did not extend be-
yond proofreading, with all other work undertaken by
the wider ECLS team. None of the other MRC START
investigators were involved in the development of the
original PIB.
Recruitment intervention
A revised PIB and accompanying GP letter were devel-
oped using the performance-based user-testing process.
This was an evidence-based [22], expert-led process that
consisted of optimising the readability, appearance and
navigation of the PIB and letter. The majority of the
content of the original PIB was retained, but the PIB was
re-written and re-designed on the basis of feedback from
the user-testing process. This process was led by PK
from the START team, who has significant experience
and expertise in writing for patients, with user testing
being undertaken by Luto Research Limited (Leeds, UK).
Healthy volunteers with a similar age, educational and
employment socio-demographic profile as the sample
for ECLS were recruited for the performance-based user
testing. Individuals who had participated in any health-
care trial or user testing in the preceding 6 months were
excluded. An iterative user-testing process was followed
[23–26] which involved objectively evaluating the ability
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of patients to locate and understand key information
contained in the PIB and letter.
Four rounds of user testing were undertaken with ten
volunteers in each round. The combined mean age of
volunteers across the four rounds was 63 years (range,
51–75 years); 50% were female; 37.5% had completed
their education at the UK minimum age (14–16 years,
depending on participant age), 42.5% completed educa-
tion at age 18 years, and 20% had higher education
(graduates); and 52.5% were retired, 42.5% were
employed and 5% were unemployed. At each round, vol-
unteers were presented with a single version of the PIB
and invitation letter, which they were then asked to read.
Then each volunteer was asked to find information in
the PIB or letter, using 20 structured questions [23, 24].
Seventeen of these questions focused on the PIB, and
three focused on the invitation letter. To test the organ-
isation of the information, volunteers were asked to
identify the answer in the PIB or letter; to test under-
standing, they were asked to provide the answer in their
own words. The questions focused on the following:
1. The ECLS trial’s nature and aims
2. The process and meaning of consent in ECLS
3. ECLS trial procedures
4. Safety, efficacy and nature of the intervention being
evaluated in ECLS
Round 1 involved testing the control ECLS materials,
consisting of a 32-page, A5-sized booklet in colour and a
two-sided, A4-sized participant invitation letter, which
contained an overview of the study on one side and con-
tact details of the ECLS trial team on the other with a
tear-off slip. Rounds 2–4 involved versions of the opti-
mised information materials. After rounds 2–4, revisions
were made to the materials in response to the obtained
user-testing data. If volunteers had difficulty with under-
standing, it signified a need to revise the wording, and if
they had difficulty finding an answer, it signified a need
to amend the document’s organisation or navigation.
Table 1 below lists the main changes made to the PIB
following user testing, which is also attached as Add-
itional file 4. Optimisation of the PIB also involved pro-
fessional graphic design by a company with significant
expertise in designing patient communication materials
(Additional file 4).
The changes to the accompanying invitation letter
were as follows: the letter was shortened by removal of
content duplicated in the PIB; ‘bullet points’ were added;
a 10-point summary of the ECLS trial was printed onto
the reverse of the letter; and a tear-off reply slip was
placed at the foot of the letter, so that letter text was
retained. Additional file 5 shows the changes made to
the invitation letter.
Outcome measures
The primary outcome was the number of patients
recruited into the ECLS trial. The secondary outcome
was the proportion of patients expressing an interest in
participating in ECLS.
Sample size calculation
The recruitment trial was powered to detect a significant
improvement in recruitment rate into ECLS, defined as
an absolute increase of 5% above baseline. Baseline
response rates for the first five ECLS practices were
around 20% (December 2013), although patient ineligi-
bility and difficulties contacting some people reduced
the 20% response rate to a recruitment rate of approxi-
mately 14% in later practices. For a baseline of 20%
recruitment, a sample size of approximately 2000 pa-
tients was estimated to provide 80% power and alpha of
0.05 for a 5% minimally important increase in recruit-
ment between the intervention PIB and the control PIB.
Randomisation
Potential participants identified from GP lists as eligible
were randomly allocated to receive the control PIB or
intervention (user-tested PIB) and GP covering invita-
tion letter at a 1:1 ratio using the recruitment-tracking
software developed by the Health Informatics Centre,
University of Dundee, and the TCTU.
Table 1 Changes to the content and structure of the patient information brochure
Changes to content Changes to the form and structure
Added NHS Scotland logo to front page Reduced length from 32 to 30 pages
Shortened ‘foreword’ by 50%, and changed heading to ‘Introduction’ Moved ‘contents’ page from page 4 to page 2, and added trial team
contact details at bottom
Changed all but one of the six photographic images to reflect more
demographic diversity
Trial team contact details moved from back page to page 27
Added a trial flow chart of the participant pathway in the centre of the
booklet
Made contents list clearer and more spread out
Added summary circles of text throughout the booklet Use of short sentences, plain English, bullet points throughout
New back page, with the same image as front page (map of Scotland) with
NHS logo
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Statistical methods
Analyses were conducted in line with a standard statis-
tical plan developed at Barts and the London Pragmatic
Clinical Trials Unit. We initially described outcomes
separately by arm for patients who expressed an interest
in the study and those who were recruited into ECLS.
We then compared these using logistic regression. Ana-
lyses followed the intention-to-treat principle and were
conducted using Stata version 14 software (StataCorp,
College Station, TX, USA). An independent statistician
(VM) who conducted analyses remained blind to alloca-
tion until the analyses were complete.
Results
A total of 2262 patients were randomised for the
SWAT, of whom 1136 were sent the intervention PIB
and 1126 were sent the control PIB. For the primary
outcome, the proportion of patients enrolled and ran-
domised into ECLS (the host trial) was 180 of 1136
(15.8%) for those sent the intervention PIB and 176
of 1126 (15.6%) in the control PIB group (OR = 1.016;
95% CI, 0.660 to 1.564). Figure 1 outlines the recruit-
ment flow chart for the SWAT. For the secondary
outcome, the proportion of patients who responded
positively to the invitation and expressed an interest
in trial participation was 224 of 1136 (19.7%) for pa-
tients sent the intervention PIB and 205 of 1126
(18.2%) in the control PIB group (OR = 1.103; 95% CI,
0.778 to 1.565).
Harms
We did not measure potential harms, such as percep-
tions of increased pressure to participate among patients
receiving the intervention PIB.
Discussion
Summary of main findings
We evaluated the effectiveness of optimised patient in-
formation materials on improving recruitment into a
lung cancer screening trial. Being sent the optimised
patient information materials made little difference to
the proportion of patients positively responding to a trial
invitation or to the proportion being randomised.
Strengths and limitations
We systematically developed optimised patient informa-
tion materials on the basis of an established and pub-
lished process [23–26], according to a published
protocol [16], and we report our findings in line with
best practice guidance for reporting recruitment SWATs
[17]. This SWAT was fully powered and used an a priori
sample size calculation, unlike most SWATs, including
those conducted as part of the MRC START project,
which set sample sizes on the basis of convenience [27].
In line with the statistical analysis plan, we undertook
the analysis according to the initial randomisation. How-
ever, although in the SWAT all the initial invitations
were correctly sent as per random allocation to the
intervention or control PIB, the ECLS team sent out
Fig. 1 Flow chart of participant response and recruitment. Based on the guidelines for reporting embedded recruitment trials, which adapt Consolidated
Standards of Reporting Trials (CONSORT) for embedded recruitment trials [17]. MRC START Medical Research Council Systematic Techniques for Assisting
Recruitment to Trials study
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further reminders in two practices to patients who had
not responded, in the intervention as well as in the
control arm of the SWAT, which were not optimised or
randomised. The use of these reminders was a capacity
decision, and at the time of the SWAT, not all patients
were sent reminders; this was because sending out more
fresh invitations through newly recruited GPs led to a bet-
ter recruitment return than reminding non-responders.
However, because the reminder letters were not rando-
mised, their use may have diluted the effect of the recruit-
ment intervention, although this effect is mitigated
because we aimed to identify differences in proportions
between the intervention and control groups, rather than
absolute levels. This highlights some of the issues with
undertaking recruitment SWATs, including difficulties in
aligning the SWATand host trials [28].
A limitation of our study is that we were unable to
gather data to assess any moderators of the effect of the
intervention, such as age, gender, ethnicity or socioeco-
nomic status, which may have provided additional infor-
mation on the impact of the intervention in different
groups. It was not the aim of the study to undertake
qualitative interviews with patients sent the trial infor-
mation, so we were not able to explore the wider impact
of optimised patient materials beyond recruitment rates.
There are also a number of different ways in which the
intervention PIB was optimised (we were evaluating a
particular way of producing a PIB, rather than any single
change to the PIB), thus in the absence of a process
evaluation or a series of trials of individual PIB changes,
it is difficult to determine whether any single change or
different combination of changes may have been more
effective. The user-testing process may have had a posi-
tive impact in its own right by improving readability and
ease of comprehension and therefore may have led to
better engagement with the trial; however, we did not
assess this.
In comparison with the materials used in many clinical
trials, the original PIB was of high quality, with use of
colour photographs and developed by a highly experi-
enced trials team. Additionally, the original PIB was
proofread by an ECLS co-investigator who was a START
co-investigator. Thus it may not have been representa-
tive of the typical PIB developed by trial teams. This
may have limited the potential additional benefit of the
user-testing process and may explain the lack of differ-
ence between the intervention and control groups. How-
ever, our present findings with an OR of 1.016 (95% CI,
0.660 to 1.564) are in line with those of the three other
SWATs undertaken as part of START, where the ORs of
the user-tested versus control leaflets were as follows:
1.01 (95% CI, 0.71–1.45) [29], 1.12 (95% CI, 0.78 to 1.61)
[18] and 1.63 (95% CI, 1.00 to 2.67) [18]. Therefore, all
current SWATs to date have found little or no effect of
the intervention PIB compared with the control PIBs,
suggesting that proofreading of the control PIB by a
START co-investigator did not significantly impact the
control leaflet in this current SWAT. The latest
Cochrane review also undertook a meta-analysis of these
SWATs with an overall risk difference estimate of 1%
(95% CI, − 1% to 3%). The START ECLS risk difference
is 0% (95% CI, − 3% to 3%) and so is entirely consistent
with the other three. Trialists now routinely involve pa-
tients and the public to assist with developing informa-
tion leaflets for patients, which may reduce the relative
benefits of user testing.
In this SWAT ‘harm’ could include reduced recruit-
ment in the intervention PIB group. We therefore evalu-
ated a two-tailed hypothesis for the primary and
secondary outcomes, which accepted that sending the
recruitment intervention to potential participants could
cause benefit or loss to recruitment for the host trial.
Although patients not being recruited represent a loss to
the host trial, for the patient, not being enrolled in the
trial may not be harmful, because the patient may have
made an informed decision not to participate. The
results demonstrate that the recruitment intervention
was not effective for increasing response and randomisa-
tion rates.
Comparison with existing literature
This SWAT adds to the small but emerging literature on
the effects of modified information on trial recruitment.
In the Cochrane review of recruitment interventions [9],
three trials explored the impact of supplementary writ-
ten material on recruitment and found little evidence of
benefit. As part of the MRC-START programme, this
article reports the fourth SWAT evaluating the effects of
optimised participant information materials on trial
recruitment in different trial contexts [18, 29]. This will
enable us to determine the effectiveness of the interven-
tion within each individual host trial and across different
trial contexts and patient populations, using a
meta-analysis. We are taking this approach because
recruitment interventions may have different impacts
according to the specific contexts, trial interventions
and patient populations. In this specific SWAT, we
tested the intervention in the context of a screening
trial. Previous SWATs of the same intervention have
been undertaken in a falls prevention trial [29], and in
two trials delivering telehealth interventions for patients
with cardiovascular disease and depression [18]. These
trials have shown small increases in the numbers of pa-
tients positively responding and enrolling; however, such
increases were not statistically significant. This SWAT
shows similar results in a small but statistically
non-significant increase in response and recruitment
rates. In this SWAT, the proportions of patients
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responding in both intervention (19.7% response; 15.8%
enrolled) and control (18.2% response; 15.6% enrolled)
groups were higher than in our previous trials; for ex-
ample, the Healthlines Depression recruitment SWAT
achieved recruitment rates of 6.3% in the intervention
group versus 4% in the control group (OR = 1.63; 95%
CI, 1.00 to 2.67) [18]. This may have been a consequence
of the use of reminder letters in both the intervention
and control groups. All current SWATs of this enhanced
PIB intervention have been compared with original PIBs
developed by highly experienced host trial teams based
within UK Clinical Research Collaboration-accredited
Clinical Trials Units, which have some of the most expe-
rienced teams delivering trials in the United Kingdom. It
may be that the optimised leaflets may be found to be
more effective if compared with leaflets developed by
less experienced trial teams in the United Kingdom or
elsewhere.
Implications for recruitment research
As part of the START programme we have under-
taken a series of SWATs of optimised participant in-
formation materials to determine their overall
effectiveness within individual trials and across differ-
ent trial contexts. In START we have demonstrated
the feasibility of developing and evaluating recruit-
ment interventions in multiple ongoing trials. Future
research should focus on reducing uncertainty around
the effect of existing interventions used to improve
recruitment (such as telephone reminders) and devel-
oping and evaluating new interventions to support
trial recruitment, especially those interventions target-
ing the education and training of trial recruiters,
which has been highlighted as a priority topic around
recruitment into trials [30, 31]. Improving the evi-
dence base around recruitment has the potential to
increase recruitment rates and increase the proportion
of trials delivering on time.
Conclusions
We evaluated the effectiveness of optimised patient
information materials on recruitment into a trial of a
screening test for lung cancer. Optimised patient in-
formation materials did not increase the proportion
of patients positively responding or being randomised.
This SWAT adds to the evidence base around trial re-
cruitment and will contribute to a future
meta-analysis of the effectiveness of optimised infor-
mation materials as part of the MRC-funded START
project and as part of the Cochrane systematic review
of recruitment interventions, which is led by a mem-
ber of our team. Further interventions addressing
identified priorities for recruitment research should
be developed and evaluated using SWATs.
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